GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Current Accrued Expense

Noxopharm (ASX:NOX) Current Accrued Expense : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Noxopharm Current Accrued Expense?

Noxopharm's Current Accrued Expense for the quarter that ended in Dec. 2023 was A$0.00 Mil.


Noxopharm Current Accrued Expense Historical Data

The historical data trend for Noxopharm's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Current Accrued Expense Chart

Noxopharm Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Current Accrued Expense
Get a 7-Day Free Trial - - - - -

Noxopharm Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Noxopharm Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Noxopharm Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Noxopharm's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Noxopharm (ASX:NOX) Business Description

Traded in Other Exchanges
Address
60 Linksley Ave, Glenhaven, NSW, AUS, 2156
Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm (ASX:NOX) Headlines

No Headlines